Genetic Epidemiology of Chagas Disease Progression
恰加斯病进展的遗传流行病学
基本信息
- 批准号:8101324
- 负责人:
- 金额:$ 77.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-01 至 2013-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAreaBiological AssayBlood BanksBrazilCardiacCardiomyopathiesCardiovascular PathologyCentral AmericaChagas DiseaseCharacteristicsChronicDNADNA ResequencingDataData CollectionData SetDevelopmentDisease OutcomeDisease ProgressionDrug Delivery SystemsElectrocardiogramFamilyFutureGenesGeneticGenetic DeterminismGenomeGenotypeGoalsGrantHealthHealthcareHeart DiseasesIncidenceIndividualInfectionKnowledgeLatin AmericaLeadLongitudinal StudiesMeasuresMolecularMotivationOrganismParasitemiaPathway interactionsPharmaceutical PreparationsPharmacologic SubstancePhasePhenotypePopulation StudyPredispositionPrevalenceProcessPublic HealthReadingResearchResearch DesignRiskSamplingScanningSerumSeverity of illnessSouth AmericaSurveysSystems AnalysisTechnologyTestingTrypanosoma cruziUnited StatesUniversitiesVaccinesVariantWorkbasecare burdencohortdensitydesigndrug developmenteffective therapyexperiencefollow-upforestgenetic analysisgenetic epidemiologygenetic pedigreegenetic variantgenome wide association studygenome-wideimprovednovelresponserural areatransmission process
项目摘要
DESCRIPTION (provided by applicant): Chagas disease affects 17 million people and a further 100 million people are at risk for infection with Trypanosoma cruzi, the parasitic cause of Chagas disease, throughout Latin America. Approximately 300,000 people develop Chagas disease each year resulting in an enormous health care burden. The prevalence of T. cruzi infection is growing in the U.S., and surveys of blood bank samples (from apparently healthy individuals) show prevalence rates ranging between 1 in 5000 and 1 in 9000. Approximately 40% of infected individuals will remain asymptomatic throughout their lives. However, about 60% of infected individuals will progress to chronic Chagas disease. The cardiac form of Chagas disease is highly debilitating, resulting in progressive cardiomyopathy. There is no vaccine for T. cruzi infection and available drugs are of questionable efficacy in reducing parasitemia after the initial acute phase of infection. There are no effective pharmaceutical treatments for Chagas disease. Unfortunately, the mechanisms underlying development of chronic Chagas disease remain poorly understood. We will assess ECG and immunological phenotypes correlated with Chagas disease in 1000 individuals who are infected with T. cruzi and who belong to large extended pedigrees. The goal of the project is to identify genetic determinants of progression to the cardiac form of Chagas disease in this sample. These individuals will be characterized for one million SNPs to facilitate genome-wide analyses designed to identify genes influencing disease progression. An additional 500 uninfected individuals from these same pedigrees will be employed to aid the identification of genetic variants that specifically are involved in genotype-by-infection interaction. The 10 most promising genes will then be resequenced to identify the functional variants responsible for the observed phenotypic variation in disease progression. Finally, a confirmation study of the best associated sequence variants will be performed in 500 unrelated infected cases with severe cardiac disease and 500 unrelated infected asymptomatic controls. Knowledge of the genes that are causally involved in determination of disease progression will significantly advance our knowledge of mechanisms underlying development of Chagas disease, suggest new pathways to be considered in potential drug development efforts, and allow matching of available pharmaceutical compounds to novel drug targets suggested by genetic analysis. PUBLIC HEALTH RELEVANCE: Chagas disease affects 17 million people and a further 100 million people are at risk for infection with Trypanosoma cruzi, the parasitic cause of Chagas disease, throughout Latin America. Approximately 300,000 people develop Chagas disease each year resulting in an enormous health care burden. There is no vaccine for T. cruzi infection and no effective for chronic Chagas disease. Knowledge of the genes that are causally involved in determination of disease progression will significantly advance our knowledge of mechanisms underlying development of Chagas disease, suggest new pathways to be considered in potential drug development efforts, and allow matching of available pharmaceutical compounds to novel drug targets suggested by genetic analysis.
描述(由申请人提供):南美锥虫病影响1700万人,另有1亿人有感染克氏锥虫的风险,克氏锥虫是南美锥虫病的寄生虫原因。每年大约有30万人患上恰加斯病,造成巨大的卫生保健负担。T.克鲁兹感染在美国不断增长,对血库样本(来自表面健康的个人)的调查显示,患病率在1/5000至1/9000之间。大约40%的感染者将在其一生中保持无症状。然而,大约60%的感染者会发展成慢性恰加斯病。心脏形式的恰加斯病是高度衰弱的,导致进行性心肌病。目前还没有针对T.克氏感染和现有药物在减少感染初期急性期后的寄生虫血症方面的效力值得怀疑。没有有效的药物治疗南美锥虫病。不幸的是,慢性恰加斯病的潜在发展机制仍然知之甚少。我们将在1000例感染锥虫病的个体中评估与锥虫病相关的ECG和免疫表型。cruzi和属于大的扩展谱系。该项目的目标是确定该样本中发展为心脏型恰加斯病的遗传决定因素。这些个体将被表征为100万个SNP,以促进旨在鉴定影响疾病进展的基因的全基因组分析。来自这些相同家系的另外500名未感染个体将用于帮助鉴定特异性参与基因型-感染相互作用的遗传变异。然后将对10个最有希望的基因进行重新测序,以确定导致疾病进展中观察到的表型变异的功能变体。最后,将在500例无亲缘关系的严重心脏病感染病例和500例无亲缘关系的无症状感染对照中进行最佳关联序列变异的确认研究。了解与疾病进展有关的基因将大大提高我们对恰加斯病发展机制的认识,提出在潜在药物开发工作中要考虑的新途径,并允许将可用的药物化合物与遗传分析提出的新药靶点相匹配。公共卫生相关性:南美锥虫病影响到1 700万人,另有1亿人面临感染克氏锥虫的风险,克氏锥虫是南美锥虫病的寄生虫病因。每年大约有30万人患上恰加斯病,造成巨大的卫生保健负担。目前还没有针对T.克氏锥虫病对慢性锥虫病无效。了解与疾病进展有关的基因将大大提高我们对恰加斯病发展机制的认识,提出在潜在药物开发工作中要考虑的新途径,并允许将可用的药物化合物与遗传分析提出的新药靶点相匹配。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SARAH A. WILLIAMS-BLANGERO其他文献
SARAH A. WILLIAMS-BLANGERO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SARAH A. WILLIAMS-BLANGERO', 18)}}的其他基金
Genetic Epidemiology of Chagas Disease Progression
恰加斯病进展的遗传流行病学
- 批准号:
8310010 - 财政年份:2009
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Epidemiology of Chagas Disease Progression
恰加斯病进展的遗传流行病学
- 批准号:
7923210 - 财政年份:2009
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Epidemiology of Chagas Disease Progression
恰加斯病进展的遗传流行病学
- 批准号:
7590884 - 财政年份:2009
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Determinants of Human Transcriptional Aging
人类转录衰老的遗传决定因素
- 批准号:
7354276 - 财政年份:2008
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Determinants of Human Transcriptional Aging
人类转录衰老的遗传决定因素
- 批准号:
8220802 - 财政年份:2008
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Determinants of Human Transcriptional Aging
人类转录衰老的遗传决定因素
- 批准号:
7844851 - 财政年份:2008
- 资助金额:
$ 77.68万 - 项目类别:
Genetic Determinants of Human Transcriptional Aging
人类转录衰老的遗传决定因素
- 批准号:
8026871 - 财政年份:2008
- 资助金额:
$ 77.68万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 77.68万 - 项目类别:
Research Grant